Some rounds tell you more about the investors than the science. TippingPoint Biosciences just closed an oversubscribed $4.5 million seed round, and look who’s at the table: the American Cancer Society’s BrightEdge venture arm, the Sontag Innovation Fund (one of the largest private funders of brain tumor research in North America), and WeCAN. These aren’t financial tourists. These are organizations that exist because children die from brain tumors and nobody has a drug for them.
The target? Diffuse Intrinsic Pontine Glioma — DIPG. If you’re not familiar, count yourself lucky. It’s a brainstem tumor that primarily strikes children, is inoperable, has no approved therapy, and is almost universally fatal within months of diagnosis. The median survival hasn’t meaningfully changed in decades.
TippingPoint’s angle is genuinely novel. Co-founded by Dr. Laura Hsieh (CEO) and Dr. Geeta Narlikar (a UCSF professor and National Academy of Sciences member), the company built its platform on a fundamental insight about chromatin biology: cancer cells don’t just have mutant genes — they have defective DNA packaging. When chromatin structure goes wrong, normal growth brakes fail. Current approaches target individual chromatin factors that also function in healthy cells, which means toxicity. TippingPoint’s platform targets the protein-protein and protein-DNA networks that are unique to the cancer chromatin state.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
The round was co-led by SOSV (TippingPoint graduated from their IndieBio accelerator, Batch 14, where peers voted them “Killer of the Week”) and LKS Fund, with participation from Sazze Partners, Freeflow Ventures, and StoryHouse Ventures among others. At eight employees and a San Francisco HQ, this is early. Discovery stage. No drug candidates disclosed yet.
But that’s kind of the point with a story like this. The science came out of Dr. Narlikar’s UCSF lab, where the team figured out how to screen for small molecules that specifically modulate disease chromatin networks — something the company says has never been druggable before. The platform isn’t limited to DIPG either; it could extend to other hard-to-treat cancers, neurodegenerative diseases, and developmental disorders. They’ve already won the 2023 Astellas Future Innovator Prize and collected golden tickets from ONO Pharma pitch competitions.
$4.5 million isn’t going to cure DIPG. But it’s going to fund the work that might tell us if targeting chromatin architecture — rather than individual chromatin factors — is a viable path. For the families behind these impact investors, that question is worth everything.
